AML
Conference Coverage
LSC phenotypes correlate with prognosis in AML
© ASCO/Rodney White CHICAGO—Researchers say they have identified 3 leukemia stem cell (LSC) phenotypes that are correlated with cytogenetic/...
News
DART molecule proves active against AML
Photo by Sakurai Midori An artificial antibody that redirects T cells to target cancer cells shows promise for treating acute myeloid leukemia (...
News
Dexrazoxane Tx did not affect overall survival in pediatric leukemia and lymphoma
Key clinical point: Treatment with dexrazoxane was not associated with an increased risk for cancer relapse or death. Major finding: For pediatric...
News
FDA grants inhibitor fast track designation for AML
The US Food and Drug Administration (FDA) has granted fast track designation to AG-120 for the treatment of patients with acute myelogenous...
News
Combo targets AML, BL in the same way
Image by Ed Uthman Combining a cholesterol-lowering drug and a contraceptive steroid could be a safe, effective treatment for leukemias,...
News
FDA grants drug orphan designation for AML
Image by Lance Liotta The US Food and Drug Administration (FDA) has granted orphan designation for GMI-1271 to treat acute myeloid leukemia (AML...
News
Group learns how protein promotes AML
A few years ago, researchers discovered that inhibiting the protein BRD4 can treat acute myeloid leukemia (AML). However, the mechanism that...
Conference Coverage
Agent preferentially targets FLT3-ITD AML
PHILADELPHIA—Preclinical research suggests a novel agent has preferential activity in acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3...
News
Targeting receptors to better treat AML
Photo courtesy of UT Southwestern Medical Center Preclinical research suggests that certain receptors containing the immunoreceptor tyrosine-...
Conference Coverage
Susceptibility to 2nd cancers in WM/LPL survivors
PHILADELPHIA—A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM...
Conference Coverage
CDK inhibitor proves active against AML, ALL
PHILADELPHIA—Preclinical research suggests a cyclin-dependent kinase (CDK) inhibitor is active against acute leukemias, particularly those with...